Tafasitamab and NK cells

Phase 2Cell therapy

Tafasitamab and NK cells is one of 5 small molecule programs targeting Autoimmune Disorders. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DisordersRecruiting

Autoimmune DisordersPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Autoimmune Disorders

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 3

Tafasitamab

Incyte

Phase 2

1 4

Darzalex

Johnson & Johnson

Preclinical

1 5

Tafasitamab and NK cells

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Autoimmune Disorders

NCT06434363

Clinical

Trials by Indication[1]

Autoimmune Disorders1 trial

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06434363·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tafasitamab and NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tafasitamab and NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tafasitamab and NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Tafasitamab and NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Autoimmune Disorders1 trial

References

Drug Info

Quick Facts

Related News